SCLC: second-line therapy with lurbinectedin and doxorubicin on trial

被引：0
|
作者：
Simon, Annika
机构：
来源：
PNEUMOLOGIE | 2023年 / 77卷 / 10期
关键词：
D O I：
10.1055/a-2038-6751
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Lurbinectedin ist ein synthetischer Wirkstoff, der die onkogene Transkription des Erbguts hemmt und von der amerikanischen Arzneimittelbehorde FDA eine Zulassung zur Zweitlinientherapie bei kleinzelligem Bronchialkarzinom (SCLC) erhalten hat. Aix et al. wollten nun Sicherheit und Wirksamkeit der Kombination aus Lurbinectedin und Doxorubicin als Zweitlinientherapie bei SCLC prufen und haben eine Phase-III-Studie durchgefuhrt.
引用
收藏
页数：1
相关论文
共 50 条
  • [11] A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer
    Cheng, Ying
    Wu, Chunjiao
    Wu, Lin
    Zhao, Jun
    Zhao, Yanqiu
    Chen, Lulu
    Xin, Ying
    Zhang, Liang
    Pan, Pinhua
    Li, Xingya
    Li, Juan
    Dong, Xiaorong
    Tang, Ke
    Gao, Emei
    Yu, Fei
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [12] A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer
    Ying Cheng
    Chunjiao Wu
    Lin Wu
    Jun Zhao
    Yanqiu Zhao
    Lulu Chen
    Ying Xin
    Liang Zhang
    Pinhua Pan
    Xingya Li
    Juan Li
    Xiaorong Dong
    Ke Tang
    Emei Gao
    Fei Yu
    Scientific Reports, 14
  • [13] Real-world (RW) outcomes of second-line (2L) small cell lung cancer (SCLC) patients treated with lurbinectedin
    Estrin, A.
    Wang, X.
    Boccuti, A.
    Prince, P.
    Gautam, N.
    Rengarajan, B.
    Li, W.
    Lu, T.
    Cao, Y.
    Naveh, N.
    D'Agostino, R.
    Ben-Joseph, R.
    Ganti, A. K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1250 - S1250
  • [14] Lurbinectedin/Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial
    Paz-Ares, L.
    Ciuleanu, T.
    Navarro, A.
    Fulop, A.
    Cousin, S.
    Bonanno, L.
    Smit, E.
    Chiappori, A.
    Olmedo, M. E.
    Horvath, I.
    Grohe, C.
    Lopez-Vilarino, J. A.
    Nunez, R.
    Nieto, A.
    Cullell, M.
    Vasco, N.
    Kahatt, C.
    Zeaiter, A.
    Carcereny, E.
    Roubec, J.
    Syrigos, K.
    Lo, G.
    Barneto, I.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S844 - S845
  • [15] Retrospective review of doxorubicin plus sorafenib as second-line therapy in hepatocellular carcinoma (HCC)
    Abou-Alfa, Ghassan K.
    Ma, Jennifer
    O'Reilly, Eileen Mary
    Gansukh, Bolorsukh
    Chou, Joanne F.
    Capanu, Marinela
    Saltz, Leonard
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [16] Second-line chemotherapy for small-Cell Lung Cancer (SCLC)
    Kim, Young Hak
    Mishima, Michiaki
    CANCER TREATMENT REVIEWS, 2011, 37 (02) : 143 - 150
  • [17] The examination of the second-line chemotherapy in SCLC patients with interstitial lung disease
    Ozaki, R.
    Nokihara, H.
    Yabuki, Y.
    Mitsuhashi, A.
    Yoneda, H.
    Otsuka, K.
    Ogino, H.
    Nishioka, Y.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [18] An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer
    Patel, Shetal
    Petty, William Jeffrey
    Sands, Jacob M.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [19] Effective Alternative for Second-Line Therapy
    不详
    OBESITY FACTS, 2009, 2 (01) : 57 - 57
  • [20] Axitinim believe in Second-Line Therapy
    Roos, Frederik
    AKTUELLE UROLOGIE, 2012, 43 (03) : 135 - 137
12345